First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer.
Saved in:
| Title: | First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer. |
|---|---|
| Authors: | Shapiro RM; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Sheffer M; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Booker MA; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, USA., Tolstorukov MY; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, USA., Birch GC; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Sade-Feldman M; Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA., Fang J; Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Boston, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA., Li S; Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA., Lu W; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA., Ansuinelli M; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Dulery R; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.; Department of Clinical Hematology and Cellular Therapy, Sorbonne University, Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris, Inserm UMRs 938, Centre de recherche Saint-Antoine, Paris, France., Tarannum M; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Baginska J; Center for Immuno-oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, USA., Dwivedi N; Cell Transplant Therapy, CareDx Inc, Brisbane, CA, USA., Kothari A; Cell Transplant Therapy, CareDx Inc, Brisbane, CA, USA., Penter L; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Abdulhamid YZ; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Kaplan IE; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Khanhlinh D; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Uppaluri R; Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Redd RA; Department of Data Science, Dana-Farber Cancer Institute, Boston, USA., Nikiforow S; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Koreth J; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Ritz J; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Wu CJ; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Soiffer RJ; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Hanna GJ; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. glenn_hanna@dfci.harvard.edu.; Center for Immuno-oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, USA. glenn_hanna@dfci.harvard.edu., Romee R; Division of Transplantation and Cellular Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. rizwan_romee@dfci.harvard.edu. |
| Source: | Journal of hematology & oncology [J Hematol Oncol] 2025 Feb 14; Vol. 18 (1), pp. 17. Date of Electronic Publication: 2025 Feb 14. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1756-8722 |
|---|---|
| DOI: | 10.1186/s13045-025-01669-3 |
